INTRODUCTION
It is well established that the treatment of choice for severe symptomatic aortic valve stenosis is valve replacement. Since the first surgical implantation in 1960, (1) this procedure has gained a multitude of evidence to support its use with an estimated one million implants to date. In high volume centres, 30-day mortality rates as low as 4% have been reported. (2) (3) (4) Despite this, up to a third of patients are not even referred for valve replacement due to perceived high risk. (5) This has lead to a search for less invasive alternatives. Alain Cribier did the first transcatheter aortic valve implantation in 2002 (6) and this was followed by huge interest in the Summer 2012 
Screening
Screening was performed by at least a cardiologist and a surgeon.
The reasons for turning patients down for TAVI included poor general health (opinion of more than one team member); insufficient symptoms; conventional surgery was a realistic possibility; the aortic annulus measured <18 or >26mm (as delineated by TEE); and refusal by medical aid to fund the procedure.
Patients underwent transthoracic echocardiography (TTE) to assess severity of disease as well as annulus size measurement and suitability of the landing zone of the prosthesis. Recent coronary angiogram was required, but no coronary intervention or infarction was allowed within the month preceding the TAVI. Coronary revascularisation was performed only if deemed to be clinically relevant (generally, this implied the presence of regular angina). The ileo-femoral arteries were assessed by conventional angiography or CT scan. Transfemoral implantation was the preferred route, unless ileo-femoral anatomy was unfavourable due to tortuosity, inadequate calibre and extensive calcification.
CT scan of the aortic root was performed in some of the patients to assess the annulus size. This modality tends to oversize the annulus, requires extra contrast and local expertise is limited. We therefore performed it only in a limited number of cases.
The final decision on the valve size was made with an annulus measurement using transoesophageal echocardiography (TEE).
The procedures
Although the techniques for transfemoral and transapical aortic valve implantation have been described previously, (7) certain detail is retained in this report as it is required to put the complications and outcomes in perspective. Immediate success was assessed with supra aortic contrast injection as well as with TEE. The puncture site in the groin was closed surgically and the result of this closure was assessed with a contrast injection through the pigtail catheter in the contralateral groin.
The technique for the SAPIEN XT TM implantation is similar except that the valve is mounted on the delivery catheter, behind the balloon. Once exited from the insertion sheath into the abdominal aorta, the balloon is pulled back into the crimped valve and clicks into place. The mounted valve is then advanced further up the aorta.
For the transapical approach, a left mini-thoracotomy was made with liberal infiltration with long acting local anaesthetic. The left ventricular apex was exposed and pre-closed with plegetted purse string sutures. After puncture of the left ventricular apex, the rest of the procedure is largely the same as for transfemoral approach, except that the valve is mounted in the opposite orientation on the balloon catheter.
Data collection
An echocardiogram was performed prior to discharge and patients were then seen at 30 days and where applicable, 6 months and 1 year. We will report only the 30 day data.
Transthoracic echocardiography was performed before hospital discharge and then at 30 days and 1 year at the implantation centre.
Aortic valve area was calculated with the continuity equation (via the velocity-time integral method) from data derived before and after device implantation.
Measurement of the left ventricular outflow tract for calculations of aortic valve area was performed with 2-dimensional imaging in a zoomed-up parasternal long-axis view. For patients located geographically far from Cape Town and unable to return to the implantation centre for further studies, these measurements were undertaken by an experienced local service.
Aortic incompetence was classified as para-valvular or valvular and graded as none, trivial, moderate and severe.
Study end-points
We assessed each patient for any complication but focussed on the following outcomes: complications (including stroke, major vascular complications requiring acute intervention or blood transfusion; conduction abnormalities requiring permanent pacing; renal failure requiring dialysis) procedural success rate; 30-day mortality; and New York Heart Association functional status after the procedure. For vascular access complications, stroke and bleeding, we used VARC-definitions.
(8)
Statistical analysis
P-values for differences in outcomes were calculated using the Mann-Whitney U equation (unless stated otherwise) and a value of ≤0.05 was considered significant.
RESULTS

Baseline characteristics
Seventy patients were included in the study cohort. Coronary revascularisation was not required in any patient after referral to our team although 3 patients had PCI procedures done in the last 6 months prior to referral to us.
FIRST EXPERIENCE WITH TAVI IN SOUTH AFRICA
Patients were old (mean age was 80) and had high predicted mortality (average logistic EuroSCORE was 26.6) (see Table 1 ). Of the 12 patients with a EuroSCORE below 20, all had either a STS score >10 and or had absolute contra-indications to surgery.
A few of these deserve special mention: 
Procedural outcomes
Procedural success was achieved in all but 2 patients (97%). Both patients died acutely (see under Complications below). Valves were placed successfully in all patients who survived the initial procedure. See Table 2 for detail. 30-day mortality was 7.1% in a cohort with a predicted 30-day mortality of 26% (according to log EuroSCORE). In an effort to delineate a potential learning curve, we compared procedural parameters for the first half of our experience (cases 1-35) with the second half (cases 36-70). This is delineated in Table 3 .
Complications
Several complications occurred, underlining how frail these patients are. They include ileus with aspiration; Stevens-Johnson syndrome coronaries. This was aspirated, she was thrombolysed and the left main was stented. After initial recovery, she deteriorated again and we could not resuscitate her successfully. A medicolegal autopsy was performed but the result was not at our disposal.
Renal failure requiring dialysis was not seen, despite a mean contrast usage of 112ml. This was likely due to good renal function prior to the procedure with a mean serum creatinine level of 110umol/l (range 60-254).
Echocardiographic assessment revealed that the mean gradient across the aortic valve fell from 54 to 11.6mmHg (see Figure 1) .
The mean AR grade remained low at 1 post op and 13% of cases had grade 1 or 2 AR but no cases with >grade 2 AR.
Most patients experienced significant symptomatic relief as depicted in Figure 2 .
The purpose of this study is to describe the short term outcome of the procedures but we do have access to 1-year mortality follow up data on 29 patients: 4 of them (14%) have died. Of these, only one was procedural. The others occurred more than 30 days postprocedure. These patients had an average log EuroSCORE of 35%
and an average age of 85 which puts them at the higher risk end of the cohort as a whole.
DISCUSSION
Transcatheter aortic valve implantation has grown rapidly since the first implants by Cribier. The Edwards SAPIEN bioprostheses has now been approved for clinical use in the European Union and preliminary guidance for its use has been published by the National 
FIGURE 3:
Predicted 30 mortality (log EuroSCORE in blue) compared to actual 30 day mortality (%, in yellow) across different TAVI studies, including the current study (Western Cape). (10, 11, 18, 19) Gradient ( We had a high implantation success rate of 97% which compares well with more recently published figures of 90-96%. (9) (10) (11) Thirty-day mortality was also low at 7.1% which also compares well with published data of other groups, summarised in Figure 3 .
Of the 2 procedural deaths we had, both were due to factors we could not predict and, in retrospect, the team's opinion was that these complications were not predictable and we would not alter we were stricter with our selection of cases although this is not reflected in the log EuroSCORE risk prediction (26% in our cohort as compared to 29% in cohort A and 26% in cohort B of the PARTNER trial). (9, 12) Another major cause for morbidity and mortality is major vascular complications. We had a significant number of these but most were in the first half of our experience and since the introduction of the smaller calibre SAPIEN XT device, we only experienced one major vascular complication. Comparing our results to other groups is not easy, as the VARC definitions (8) were not available and therefore not used in most of these studies. Our figure of 9% major complications compares well to the 30% reported by the PARTNER trial. (9) Post-procedural MR was significantly lower when considering the group as a whole, however in individual cases, the degree of MR may have worsened or improved and predicting this change was not possible. This is similar to the observations of others. (13) Although functional MR (as opposed to MR due to structural disease of the valve) could improve in theory, this has not been validated in studies. (14) TAVI can be performed via the transfemoral route in patients who are awake. This makes the use of constant TEE monitoring virtually impossible. We feel that the benefit of having immediate access to an accurate diagnostic tool in case of a complication outweighs the risk of general anaesthesia. Furthermore, using a closure device for the femoral access site, adds to the cost of this procedure and we therefore continue to do surgical cut down in most transfemoral cases.
Technically, TAVI represents new challenges to both interventionists used to performing coronary interventions (with much smaller calibre devices) and surgeons not used to dealing with catheters and guide wires. A significant learning curve is therefore observed and despite our experience to date, this learning curve continues.
Demonstrating a learning curve from the data is not simple as the numbers are small and outliers skew the data significantly. We could however show that most of the procedure-related parameters improved with experience (Table 3) hope that the devices become more affordable in future and that it will be suitable for rheumatic heart disease.
Shortcomings of the study
Although we turned a significant number of patients down for the procedure, this data was not collected prospectively and outcomes of these patients cannot be reported. A further study on the reasons for patients being turned may provide valuable information.
Furthermore, our very low stroke rate may be explained by the fact that we did not follow all the patients up ourselves and there may have been under reporting. It has been shown repeatedly that most patients undergoing TAVI will have MRI visible micro-emboli to the brain, although clinically significant stroke is much rarer. (16,17.) Finally, this is only a report on short term data, reflecting our implantation success. Longer follow up is needed to further delineate these results.
CONCLUSIONS
With a multidisciplinary team approach and careful patient selection, TAVI can be performed by a high volume centre in South Africa with results comparable to international published outcomes.
Mortality is better than predicted by EuroSCORE, underscoring the shortcomings of this scoring system. Patient selection remains difficult and further studies are needed to improve on this.
